Advertisement
ARWR vs IONS
Which Stock Would AI Choose? Arrowhead Pharmaceuticals (ARWR) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- Arrowhead Pharmaceuticals (ARWR) has shown superior recent momentum with YTD gains of 11.57% compared to Ionis Pharmaceuticals' (IONS) 7.38%, and a remarkable 1-year return of 459% versus 148%.
- Both biotech firms specialize in RNA-targeted therapies, but ARWR boasts positive EPS ($1.60 TTM) while IONS reports losses (EPS -$2.38 TTM).
- Analyst consensus price targets suggest upside for both, with ARWR at around $83-$84 (12-14% potential) and IONS at $92-$97 (25-32% potential).
- ARWR's market cap stands at $10.37B, slightly below IONS's $12.1B, reflecting comparable scale in the competitive biotech sector.
- Upcoming catalysts include Phase 3 data readouts for both, positioning them for potential volatility amid clinical advancements.
Introduction
Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS) represent key players in the oligonucleotide therapeutics space, targeting genetic diseases through RNA interference (RNAi) and antisense technologies. This stock comparison analyzes their recent market performance, pipeline progress, and relative positioning, aiding traders seeking short-term momentum and investors focused on long-term biotech growth. With both stocks trading around $73-$74 amid broader sector recovery, understanding their contrasts in momentum, profitability, and catalysts is essential for informed decision-making in the volatile biotech landscape.
ARWR Overview and Recent Performance
Arrowhead Pharmaceuticals (ARWR) develops RNAi therapeutics aimed at silencing disease-causing genes, with a pipeline emphasizing cardiometabolic, pulmonary, and liver disorders. In recent market activity, the stock has exhibited robust upward momentum, climbing to approximately $74 with a 52-week range of $12.44-$76.76 and YTD gains of 11.57%. This performance reflects positive sentiment from Q1 fiscal 2026 results, analyst upgrades such as Morgan Stanley's Overweight rating with a $100 target, and anticipation for 2026 milestones including Phase 3 plozasiran data and zodasiran advancements. Trading volume remains elevated, underscoring investor interest in its $10.37B market cap and positive EPS trajectory.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) pioneers antisense oligonucleotide technology to modulate RNA and treat rare neurological, cardiovascular, and metabolic conditions. Recent weeks have seen the stock stabilize around $73, within a 52-week range of $29.42-$86.74, posting YTD returns of 7.38%. Key influences include positive pivotal data on zilganersen for Alexander disease presented at the AAN 2026 meeting, an upcoming Q1 2026 earnings webcast, and FDA Priority Review for its NDA with a PDUFA date in September 2026. Despite commercial revenue growth from launches like Tryngolza, profitability challenges persist, supporting its $12.1B market cap amid pipeline optimism.
Trending AI Robots
Tickeron's Trending AI Robots page features a curated selection of the top 25 AI trading bots from over 351 available, each designed to trade thousands of tickers across diverse strategies, timeframes, and market conditions. These bots deliver real-time signals via technical and fundamental analyses, with performance stats including annualized returns from +15% to +168%, win rates of 48%-88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 21 in some cases. Tailored for sectors like biotech, volatility, and growth stocks, they offer customizable risk management and multi-ticker trading. Traders can explore these high-performing options to enhance strategies amid current market dynamics.
Head-to-Head Comparison
Both ARWR and IONS operate in the biotech sector, leveraging RNA-targeted platforms—RNAi for ARWR and antisense for IONS—to address unmet needs in cardiometabolic and rare diseases. Growth drivers differ: ARWR benefits from near-term Phase 3 readouts like plozasiran, while IONS advances with zilganersen's regulatory progress and olezarsen potential. Recent momentum favors ARWR with explosive 1-year gains versus IONS' steadier climb, though IONS offers higher analyst upside. Risk factors include clinical trial outcomes and binary regulatory events for both, with ARWR showing profitability edges amid similar sector exposure and positive market sentiment.
Tickeron AI Verdict
Tickeron's AI analysis leans toward ARWR in the current environment, driven by stronger trend consistency, superior relative performance over recent periods, and aligned catalysts positioning it for potential outperformance. While IONS holds appeal through regulatory milestones, ARWR's momentum and valuation metrics suggest higher probability of near-term gains, though biotech volatility warrants caution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and IONS is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARWR’s FA Score shows that 1 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).
- ARWR’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARWR’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 3 bullish TA indicator(s).
- ARWR’s TA Score: 4 bullish, 5 bearish.
- IONS’s TA Score: 3 bullish, 5 bearish.
Price Growth
ARWR (@Biotechnology) experienced а +1.96% price change this week, while IONS (@Biotechnology) price change was -1.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.78%. For the same industry, the average monthly price growth was +90.18%, and the average quarterly price growth was +2050.65%.
Reported Earning Dates
ARWR is expected to report earnings on Aug 06, 2026.
IONS is expected to report earnings on Aug 05, 2026.
Industries' Descriptions
@Biotechnology (+0.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ARWR | IONS | ARWR / IONS | |
| Capitalization | 10.5B | 12.1B | 87% |
| EBITDA | -134.47M | -217.15M | 62% |
| Gain YTD | 12.246 | -7.376 | -166% |
| P/E Ratio | 48.72 | N/A | - |
| Revenue | 622M | 1.06B | 59% |
| Total Cash | 1.78B | 1.92B | 93% |
| Total Debt | 989M | 2.04B | 48% |
ARWR | IONS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 98 | 39 | |
SMR RATING 1..100 | 99 | 99 | |
PRICE GROWTH RATING 1..100 | 36 | 47 | |
P/E GROWTH RATING 1..100 | 33 | 64 | |
SEASONALITY SCORE 1..100 | 50 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARWR's Valuation (91) in the Biotechnology industry is in the same range as IONS (100). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
IONS's Profit vs Risk Rating (39) in the Biotechnology industry is somewhat better than the same rating for ARWR (98). This means that IONS’s stock grew somewhat faster than ARWR’s over the last 12 months.
IONS's SMR Rating (99) in the Biotechnology industry is in the same range as ARWR (99). This means that IONS’s stock grew similarly to ARWR’s over the last 12 months.
ARWR's Price Growth Rating (36) in the Biotechnology industry is in the same range as IONS (47). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
ARWR's P/E Growth Rating (33) in the Biotechnology industry is in the same range as IONS (64). This means that ARWR’s stock grew similarly to IONS’s over the last 12 months.
| ARWR | IONS | |
|---|---|---|
| RSI ODDS (%) | 7 days ago 79% | N/A |
| Stochastic ODDS (%) | 3 days ago 80% | 3 days ago 63% |
| Momentum ODDS (%) | 3 days ago 86% | 3 days ago 67% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 71% |
| TrendWeek ODDS (%) | 3 days ago 79% | 3 days ago 65% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 67% |
| Advances ODDS (%) | 3 days ago 82% | 11 days ago 67% |
| Declines ODDS (%) | 5 days ago 84% | 7 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 74% | 3 days ago 69% |
| Aroon ODDS (%) | 3 days ago 77% | N/A |
Advertisement
ARWR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with IONS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then IONS could also see price increases.
| Ticker / NAME | Correlation To ARWR | 1D Price Change % | ||
|---|---|---|---|---|
| ARWR | 100% | +0.15% | ||
| IONS - ARWR | 46% Loosely correlated | -0.74% | ||
| AXON - ARWR | 46% Loosely correlated | -1.00% | ||
| ABUS - ARWR | 42% Loosely correlated | -0.70% | ||
| DNLI - ARWR | 42% Loosely correlated | +3.04% | ||
| CYTK - ARWR | 41% Loosely correlated | +1.27% | ||
More | ||||
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been closely correlated with CYTK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if IONS jumps, then CYTK could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | -0.74% | ||
| CYTK - IONS | 66% Closely correlated | +1.27% | ||
| MLYS - IONS | 65% Loosely correlated | -1.34% | ||
| ARWR - IONS | 47% Loosely correlated | +0.15% | ||
| MNKD - IONS | 46% Loosely correlated | -2.40% | ||
| AXON - IONS | 43% Loosely correlated | -1.00% | ||
More | ||||